Stock Market Reviews

Read and share opinions on XERS (Xeris Biopharma Holdings, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock

Latest News

• Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year
  Nov 9, 2025
• Xeris Biopharma (XERS) Reports Q3 Earnings: What Key Metrics Have to Say
  Nov 6, 2025
• Xeris Biopharma (XERS) Reports Break-Even Earnings for Q3
  Nov 6, 2025
• Xeris Biopharma Posts Record Financial Results for the Third Quarter 2025
  Nov 6, 2025
• Xeris Biopharma (XERS): Evaluating Valuation as Revenue Growth and Pipeline Advances Spark Renewed Optimism
  Oct 28, 2025
• Xeris Biopharma to Report Third Quarter 2025 Financial Results on November 6, 2025
  Oct 23, 2025
• Are You Looking for a Top Momentum Pick? Why Xeris Biopharma (XERS) is a Great Choice
  Oct 20, 2025
• Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  Oct 3, 2025
• Xeris Biopharma (XERS) is a Great Momentum Stock: Should You Buy?
  Oct 3, 2025
• Xeris Biopharma Holdings, Inc. (NASDAQ:XERS): Are Analysts Optimistic?
  Oct 3, 2025
• Xeris Biopharma Holdings, Inc. (XERS) Hits Fresh High: Is There Still Room to Run?
  Oct 3, 2025
• What Makes Xeris Biopharma (XERS) a Strong Momentum Stock: Buy Now?
  Sep 9, 2025
• Xeris Biopharma Holdings, Inc. (XERS) Reports Record $71.5M Q2 Revenue
  Aug 29, 2025
• Xeris Announces Orange Book Listing of U.S. Patent for Recorlev®
  Aug 25, 2025
• Xeris Biopharma (XERS) Upgraded to Buy: Here's Why
  Aug 12, 2025
• Xeris Biopharma Holdings Second Quarter 2025 Earnings: Beats Expectations
  Aug 9, 2025
• Xeris Biopharma (XERS) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
  Aug 7, 2025